Diaxonhit develops RNA-based diagnostic tests and small molecule therapeutics for the treatment of Alzheimer's disease (AD) and cancer. Diaxonhit’s technology includes alternative RNA splicing, the process by which a single gene can produce various proteins; Genome-Wide SpliceArray platform (GWSA), a patented microarray design that incorporates a specific probe configuration, enabling an exhaustive monitoring of RNA splice variants in human, mouse, and rat; and Differential Analysis of Transcripts with Alternative Splicing technology for identifying the functionally distinct messenger RNA variants differentially expressed between two biologic samples on a genome-wide basis. It offers AclarusDx, a blood-based test for the diagnosis of AD; EHT Dx14, a breast cancer diagnostic biomarker; and EHT Dx13, a blood-based diagnostic test for prostate cancer. Diaxonhit also develops therapeutic products, such as EHT 0202, a GABAA receptor modulator and a PDE4 inhibitor that is in Phase II clinical trial for the treatment of AD; EHT/AGN 0001, a Phase II clinical trial product for pain and central nervous system indications; EHT/AGN 0002 that is in pre-clinical stage to treat pain and neurodegeneration, as well as for applications in the field of ophthalmology; EHT/AGN 0003, a pre-clinical product for opthalmology and neurodegenerative indications; and EHT 107 that is in preclinical proof-of-concept testing process for applications in the field of oncology. It has strategic collaborations with bioMérieux to develop customized SpliceArray biochips to detect cancer markers in blood samples; and Allergan to discover drugs in the fields of ophthalmology, pain, and neurodegenerative diseases, as well as a research agreement with Pfizer Inc. for the identification of AD biomarkers using the company’s GWSA platform. The company was formerly known as Exonhit S.A. and changed its name to Diaxonhit in December 2012. Diaxonhit was founded in 1997 and is headquartered in Paris, France.
diaxonhit (ALEHT:EN Paris)
65 Boulevard Masséna
Phone: 33 1 53 94 77 00
Fax: 33 1 53 94 77 07www.exonhit.com
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA |Posted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
- New York, NY | AGORAPosted: Nov 25
Sponsored Financial Commentaries
To contact DIAXONHIT, please visit www.exonhit.com. Company data is provided by Capital IQ. Please use this form to report any data issues.